Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Exercises Option to Commercialize Bispecific Antibodies Based on Joint Research with Zymeworks
May 7, 2019
- After Biogen Pullout, Salix Picks Up Rights to Mitsubishi Tanabe’s MT-1303
May 7, 2019
- Dupixent Filed for Sinusitis in Japan: Sanofi
May 7, 2019
- Astellas Looks to Fortify China Biz via Global Commercial Rejig
April 26, 2019
- Astellas’ Net Profit Soars 35% on Xtandi, Betanis
April 26, 2019
- Daiichi Sankyo Reels from Olmesartan LOE, Logs 3.2% Sales Fall
April 26, 2019
- Daiichi Sankyo to Move Up Japan Filing of DS-8201 to FY2019 H2
April 26, 2019
- CSL Behring Seeks Additional Indication for Privigen
April 26, 2019
- Ninlaro Filed in Japan for Post-Transplant Maintenance: Takeda
April 26, 2019
- Takeda Files Japan NDA for Cabozantinib, Exelixis’ RCC Treatment
April 26, 2019
- Daiichi Sankyo Aims to File Yescarta in Japan by Year-End
April 26, 2019
- Takeda Cuts FY2018 Profit Outlook on Shire Takeover
April 26, 2019
- Delgocitinib Shows Good PIII Results in Pediatric Atopic Dermatitis: JT, Torii
April 26, 2019
- Ohara Obtains Exclusive Rights to Biliary Tract Cancer Drug
April 26, 2019
- Daiichi Sells Nihonbashi Building to Raise Funds for Oncology R&D
April 26, 2019
- Fujifilm Toyama Chemical Files Solithromycin for ENT Infection Diseases
April 26, 2019
- Chugai Rings Up Record Q1 Earnings on Brisk New Drug Sales
April 25, 2019
- Boehringer’s Japan Ethical Drug Sales in 2018 Sink 18.4% on Micardis Cliff
April 25, 2019
- Mitsubishi Tanabe Slashes FY2018 Earnings Forecast
April 25, 2019
- Chugai to Erect New Manufacturing Building for Small, Middle Molecule APIs
April 25, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…